AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2018
Aug 15, 2018
65314_rns_2018-08-15_2b63a252-15f4-472c-9e32-6f921e10f778.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [222 x 64] intentionally omitted <==
ASX Release
RECEIPT OF R&D TAX REFUND
Sydney, Thursday 16 August 2018
Memphasys is pleased to announce its receipt of a $592,734 Research and Development tax refund from the Australian Taxation Office.
This refund will be used for working capital purposes, in particular, to further the commercial development of Memphasys’ Felix device for separating the best sperm from semen samples for use in human IVF.
For further information please contact:
Alison Coutts Executive Chairman +61 2 8415 7300 [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140
Postal Address Contact Details E [email protected] P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556
– 2 –